Clinical Trial Update: Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating oral azacitidine (CC-486) in combination with pembrolizumab (MK-3475) for metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CC-486 (azacitidine)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma | Phase 2 | Status: COMPLETED